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Coronavirus disease 2019 (COVID-19) pandemic imposes a 
double burden on people with cardiovascular disease (CVD). 
About 40% of hospitalized COVID-19 patients have CVD 
[1] and the clinical course of COVID-19 is more severe in 
patients with hypertension, diabetes, and CVD [2]. COVID-
19 mortality increases with comorbidities and age [3]. Cor-
rect evaluation of this double burden is challenged by three 
gaps in our knowledge: (1) the unknown confounding effect 
of age on mortality of CVD/COVID-19 patients, (2) the not 
fully understood effects of COVID-19 on the cardiovascular 
system, and (3) how antihypertensive medications target-
ing the renin–angiotensin system (RAS) might be associ-
ated with the severity of and survival to COVID-19 in CVD 
patients.
COVID-19 is caused by a new human coronavirus, severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
first identified in Wuhan, China. Early estimates of the basic 
reproduction number were around 2.2 (90% high-density 
interval 1.4–3.8) [4], and as of 11 April 2020, there were 
over 1,720,000 confirmed cases of COVID-19 and more 
than 100,000 deaths. Novel human coronaviruses have 
caused two other pandemics in less than two decades: the 
first severe acute respiratory syndrome (SARS) coronavirus 
began in late 2002 and caused around 1000 deaths. Middle 
East Respiratory Syndrome (MERS), first identified in 2012, 
has killed 862 persons so far. Due to the lack of pre-existing 
immunity to the new virus, it is reasonable to believe that 
it may infect everyone in a given population equally. How-
ever, the majority of people with COVID-19 are older than 
40 years [1], as are the majority of people with CVD.
Soon after the discovery of SARS-CoV-2, researchers 
found that virus entry into the cell is initiated by binding 
to the angiotensin-converting enzyme 2 receptor (ACE2), 
a component of RAS [5]. RAS is a complex network medi-
ating cardiovascular and renal function (Fig. 1). It plays a 
crucial role in the endocrine regulation of fluid volume and 
electrolytes. Pathological RAS hyperactivation is associated 
with acute cardiac, pulmonary, and renal damage [6]. RAS 
has also been implicated in inflammation, proliferation, and 
fibrosis in chronic pulmonary diseases such as idiopathic 
pulmonary fibrosis and pulmonary arterial hypertension 
[7]. The ACE2 receptor is an integral membrane protein 
highly expressed in the lungs and heart that physiologically 
counteracts the activity of RAS by converting the vasocon-
strictor angiotensin-II (Ang-II) to the vasodilator angioten-
sin-(1–7). Evidence from experimental studies indicates that 
a decrease in ACE2 is associated with the progression of 
type 2 diabetes mellitus [8] and myocardial hypertrophy [9]. 
Conversely, upregulated ACE2 improves glycaemic control 
in diabetes [8], prevents myocardial fibrosis, and improves 
cardiac function after myocardial infarction [10]. Known 
protective effects of ACE2 through angiotensin-(1-7) might 
be attributable to antagonism of Ang-II signalling.
SARS-CoV-2 infection produces enzymatic shedding that 
inactivates ACE2 and prevents conversion of Ang-II [11]. 
This effect could in part explain the cardiovascular and res-
piratory manifestations of COVID-19. Following a decrease 
in ACE2, an increase in vasoactive, proliferative, and profi-
brotic Ang-II leads to cardiopulmonary damage through 
hemodynamic changes such as pulmonary hypertension and 
interstitial edema followed by respiratory failure in the most 
severe cases [12]. The use of soluble ACE2 to counteract 
pulmonary damage has been studied in two phase-II trials 
involving acute lung injury or acute respiratory distress syn-
drome, and pulmonary arterial hypertension. Soluble ACE2 
has also been studied in a phase-I trial to assess its effects 
on hypoxia after exercise. In spite of its cardiometabolic 
protective function, ACE2 failed to demonstrate meaningful 
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improvement in physiological or clinical measures in its 
pharmacological form [7, 13].
Effective interventions against SARS-CoV-2 need to 
be developed rapidly. Timely sequencing of the virus has 
already led to the development of several new molecular 
targets and vaccine candidates, but even with the most opti-
mistic timetable for clinical trials and regulatory approval 
new products are not expected for around 18 months. Repur-
posing existing treatments is thus a potentially important 
short-term strategy to respond to COVID-19. Therefore, 
if proven protective in COVID/CVD patients, RAS inhibi-
tors could potentially become a standard treatment for other 
COVID patients.
RAS inhibitors, ACE inhibitors (ACEI) and Ang-II recep-
tor blockers (ARBs), are safe and efficacious in the treatment 
of patients with CVD. Their use to counteract the effects of 
the lack of function of the ACE2 protein in COVID-19 [14] 
seems more than logical and currently multiple specialty 
societies recommend that RAS inhibitors should be con-
tinued in patients who are currently under treatment [15]. 
However, both preclinical and clinical studies have shown 
that ACE2 is upregulated in patients under treatment with 
ACEI/ARBs [16]. An increase in receptor availability might 
facilitate SARS-CoV-2 replication, so this pharmacological 
approach might not be helpful for treating COVID-19 [17]. 
Therefore, beyond the theoretical pros and cons for using 
RAS inhibitors in this pandemic, there are three important 
research questions. First, is mortality in CVD patients a con-
sequence of virus entry using ACE2 receptors that might 
improve with RAS blocking? Second, could the use of 
ACEI/ARBs enhance SARS-CoV-2 replication and increase 
the severity of COVID-19? If RAS blocking increases the 
risk of severe COVID-19 and mortality in CVD patients, cli-
nicians may need to replace these drugs during treatment of 
infection. Third, could RAS inhibitors be used to treat other 
COVID patients? If found to be protective, RAS inhibitors 
may become standard-of-care therapies for this and future 
outbreaks. Current recommendations need to be based on 
the current pandemic evidence. A remarkable amount of 
knowledge about this new coronavirus has been gained in a 
short period of time. Now, rapid observational studies are 
needed to clarify possible associations and to evaluate treat-
ment strategies to reduce the double burden of COVID-19 in 
CVD patients. Narrowing these knowledge gaps may help 
identify potential effective interventions against COVID-19 
and closely related coronaviruses both in CVD and non-
CVD patients.
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Fig. 1  Renin–angiotensin system inhibition (RAS) by Angiotensin-
converting enzyme/Ang-II receptor blockers (ACEI/ARBs) and 
SARS-CoV-2 binding to ACE2 receptors. Red squares indicate RAS 
actions, green squares indicate ACE actions. Black squares indicate 
effects for each component
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